

## PATENT COOPERATION TREATY

PCT  
Corrected

REC'D 10 OCT 2002

WIPO PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

10/019165

Applicant's or agent's file reference 899-55475	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/17427	International filing date (day/month/year) 22 JUNE 2000	Priority date (day/month/year) 23 JUNE 1999
International Patent Classification (IPC) or national classification and IPC IPC(7): C12N 5/00; A01N 63/00 and US Cl.: 435/372, 383; 424/93.7		
Applicant OREGON HEALTH SCIENCES UNIVERSITY		

RECEIVED

MAR 21 2003

TECH CENTER 1600/2900

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 3 sheets.
- ☒ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
- These annexes consist of a total of 1 sheets.


## 3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

RECEIVED

MAR 21 2003

TECH CENTER 1600/2900

Date of submission of the demand 12 JANUARY 2001	Date of completion of this report 26 MARCH 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  L. BLAINE LANKFORD Telephone No. (703) 308-1235

Form PCT/IPEA/409 (cover sheet) (July 1998)\*

CORRECTED VERSION

**I. Basis of the report****1. With regard to the elements of the international application:\***☐ the international application as originally filed☒ the description:pages 1-24 , as originally filedpages NONE , filed with the demandpages NONE , filed with the letter of \_\_\_\_\_☒ the claims:pages 25-27 , as originally filedpages NONE , as amended (together with any statement) under Article 19pages 27a , filed with the demandpages NONE , filed with the letter of \_\_\_\_\_☒ the drawings:pages 1-4 , as originally filedpages NONE , filed with the demandpages NONE , filed with the letter of \_\_\_\_\_☒ the sequence listing part of the description:pages NONE , as originally filedpages NONE , filed with the demandpages NONE , filed with the letter of \_\_\_\_\_**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application (under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**☐ contained in the international application in printed form.☐ filed together with the international application in computer readable form.☐ furnished subsequently to this Authority in written form.☐ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.**4. ☒ The amendments have resulted in the cancellation of:**☒ the description, pages NONE☒ the claims, Nos. NONE☒ the drawings, sheets/fig NONE**5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\*Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/17427

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. statement**

Novelty (N)	Claims <u>1-46</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>1-46</u>	YES
	Claims <u>NONE</u>	NO
Industrial Applicability (IA)	Claims <u>1-46</u>	YES
	Claims <u>NONE</u>	NO

**2. citations and explanations (Rule 70.7)**

Claims 1-46 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest a method for enhancing hematopoiesis by implanting a hematopoiesis enhancing amount of intact vascular tissue into a patient.

----- NEW CITATIONS -----

NONE

37. The method of claim 1, wherein the vascular tissue is transplanted under the kidney capsule.
- 5 38. The method of claim 1, wherein the vascular tissue is transplanted intraperitoneally or subcutaneously.
39. The method of claim 1, wherein the vascular tissue does not form an enclosed lumen.
- 10 40. The method of claim 1, further comprising assaying hematopoiesis in a sample from the subject.
41. The method of claim 11, wherein the vascular tissue is transplanted under the kidney capsule.
- 15 42. The method of claim 11, wherein the vascular tissue is transplanted or intraperitoneally or subcutaneously.
43. The method of claim 11, wherein the vascular tissue does not form an enclosed lumen.
- 20 44. The method of claim 20, wherein the vascular tissue is at least a portion of an artery or vein.
45. The method of claim 20, wherein the subject is a non-human animal subject.
46. The method of claim 31, wherein the vascular tissue is transplanted under the kidney capsule, intraperitoneally, or subcutaneously.





.

.

.

.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/17427

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 5/00; A01N 63/00

US CL : 435/372, 383; 424/93.7

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/372, 383; 424/93.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
EAST

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,750,397 A (TSUKAMOTO et al.) 12 May 1998, see entire document.	26, 34-36
X	US 3,993,078 A (BERGENTZ et al.) 23 November 1976, see entire document.	1-33

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 AUGUST 2000

Date of mailing of the international search report

07 SEP 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

L. BLAINE LANKFORD

Telephone No. (703) 308-1235

